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ABSTRACT
Objectives: Although not recommended by practice guide-
lines, physicians frequently prescribe an antibiotic for adults
with viral pharyngitis. The ﬁnancial burden of this practice,
from the payer’s perspective, has not been previously eva-
luated. The purpose of this study was to estimate those
expenditures.
Methods: A cost-of-illness study was performed to estimate
annual expenditures of pharyngitis management from the
payer’s perspective. National Ambulatory Care Survey data
were used to represent current patterns of ambulatory care
visits and antibiotic prescriptions for adult pharyngitis. Direct
and antibiotic resistance costs were summed to estimate total
expenditures for pharyngitis management. Resistance costs
were calculated using a model linking the effect of antibiotic
consumption to the cost consequences of resistant Streptococ-
cus pneumoniae infection. Sensitivity analyses compared cost
outcomes of current practice, adherence to pharyngitis man-
agement guidelines from the Infectious Diseases Society of
America (IDSA), and nonantibiotic treatment.
Results: In the base-case analysis, reﬂecting current practice
patterns, total expenditures were $1.2 billion with antibiotic
resistance contributing 36% ($426 million). IDSA guideline
adherence decreased costs to $559 million with resistance
accounting for 6.8% ($37.9 million). Guideline adherence
plus reducing ofﬁce visits by 30% decreased costs to $372
million, with only 1.4% ($5.3 million) due to resistance.
Additional cost-savings of $88 million were realized by using
a nonantibiotic treatment strategy.
Conclusions: Current practice imposed a substantial eco-
nomic burden on the payer, while guideline adherence
resulted in cost reductions, especially in terms of resistance,
emphasizing that antibiotic prescribing habits have broad
economic consequences. Relevant stakeholders, payers, phy-
sicians, and other health-care providers should revisit efforts
to encourage adherence to pharyngitis guidelines to reduce
health-care costs.
Keywords: adults, antibiotic resistance, cost-of-illness analy-
sis, pharyngitis.
Introduction
More than 11 million patients annually with acute
pharyngitis seek medical attention in the ambulatory
care setting [1]. Like other upper respiratory infections
(URI) in adults, pharyngitis is caused by a virus in 80%
to 90% of cases [2]. Group A streptococci (GAS) is the
only bacterial etiology of pharyngitis for which antibi-
otic treatment, usually with penicillin, is routinely
recommended [2]. Accordingly, only 10% to 20% of
adult patients should receive treatment with a recom-
mended antibiotic. In contrast, ambulatory care phy-
sicians provided an antibiotic prescription from 47%
to 73% of adults with pharyngitis [3–5]. Many were
for nonrecommended, newer, and more expensive
agents [4,5]. Excessive antibiotic use can contribute to
the development of antibiotic resistance leading to the
use of more expensive drugs and more costly outcomes
from infections with resistant bacteria [6–8]. Annual
expenditures related to antibiotic resistance in the
United States were estimated to be at least $5 billion
[9]. One study indicated that more than $1.1 billion
was spent annually on unnecessary antibiotic prescrip-
tions for adults with URI [10].
To help combat the overuse of antibiotics for URI,
practice guidelines for adult pharyngitis have been cir-
culated. The American College of Physicians recom-
mends clinical indicators to identify adults with a high
probability of GAS pharyngitis [11], while those from
the Infectious Diseases Society of America (IDSA) are
more stringent, because antibiotic treatment is recom-
mended only for patients with clinical features of GAS
pharyngitis plus a positive rapid antigen detection test
(RADT) [12]. Nonetheless, 66% of physicians in a
health-care plan failed to adhere to either one of these
guidelines [3].
The cost consequences to the health-care payer of
pharyngitis management are not known. A database
examination of nearly 14,000 insured employees in
1997 found that acute pharyngitis cost the employer
$30 million in health-care beneﬁts, with outpatient
expenditures estimated at $628 per beneﬁciary.
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Nevertheless, the authors did not mention whether a
practice guideline was used to aid management deci-
sions. In addition, they reported costs in broad catego-
ries without providing detailed information about the
distribution of diagnostic and therapeutic expenditures
[13]. Therefore, we undertook a cost-of-illness (COI)
study to determine the payer’s cost of pharyngitis man-
agement incurred by: 1) current practice patterns; 2)
adherence to IDSA guidelines; and 3) no antibiotic
treatment. A COI study measures the economic burden




The current COI study was prevalence-based from the
payer’s perspective with a time horizon of 1 year. We
divided expenditures into direct and resistance costs.
Direct costs were those associated with professio-
nal services, testing, antibiotic prescriptions, and
antibiotic-induced drug rash and anaphylaxis. Resis-
tance costs were those related to hospitalization
with community-acquired pneumonia (CAP) caused
by Streptococcus pneumoniae resistant to beta-lactam
or macrolide antibiotics; referred to as drug-resistant
Streptococcus pneumoniae (DRSP). Total costs were
the sum of direct and resistance expenditures.
We used 2006 Medicare reimbursement rates to the
authors’ institution to represent unit prices for profes-
sional services, RADT, drug rash, and anaphylaxis
(Table 1). Antibiotic treatment for pharyngitis was
divided into recommended and nonrecommended
agents. Penicillin and erythromycin were considered
recommended antibiotics, while extended spectrum
penicillins, cephalosporins, macrolides, and quinolo-
nes were considered nonrecommended [5]. The cost
for a course of a recommended or nonrecommended
antibiotic was determined by multiplying its wholesale
price per dose by its suggested duration for GAS phar-
yngitis [12,17]. We then summed the treatment costs
for all the recommended or nonrecommended antibi-
otics, and divided the result by the respective number
of prescriptions for each group to arrive at the average
treatment price for a course of a recommended or
nonrecommended antibiotic (Table 1).
Characteristics of Cohorts
We used data from the National Ambulatory Medical
Care Survey (NAMCS) to create the characteristics of
the NAMCS cohort [5]. The NAMCS is administered
by the National Center for Health Statistics (NCHS)
and Center for Disease Control and Prevention. Find-
ings are based on a sample of patient visits to non-
federally funded ofﬁce-based physicians who are
primarily engaged in direct patient care. The NAMCS
utilizes a multistage probability design which involves
three stages in determining selection of patient visits:
geographic location, physician specialty, and visits
within annual practices of sampled physicians. Since
1989 the survey has been conducted annually. Data
collection is completed by the staff at the sampled
practices. Each visit is weighted by NCHS to allow
extrapolation to national ﬁgures. We used summary
data from an analysis of NAMCS data which was
designed to evaluate antibiotic prescribing for adult
pharyngitis visits during the period 1989 to 1999 [5].
In the NAMCS cohort (Table 2), the number of adults
with pharyngitis seeking ambulatory care was set at
6.7 million [5]. Also reﬂecting NAMCS data, 73% (4.9
million) of patients received an antibiotic, with 78%
(3.8 million) receiving a nonrecommended agent and
22% (1.1 million) receiving one that was recom-
mended. We estimated that 80% (5.36 million) of 6.7
million patients would receive a RADT [3]. The rates
of antibiotic-induced rash and anaphylaxis were set at
3% and 0.1%, respectively [18].
Sensitivity analyses of direct costs were done by
varying key characteristics of the NAMCS cohort. In
one analysis, we applied the IDSA practice guidelines
to the NAMCS population of 6.7 million adults. We
called this cohort IDSA-NAMCS (Table 2). In another
analysis, we applied the guidelines to a reduced popu-
lation of 4.7 million adults with pharyngitis, reﬂecting
a 30% reduction in ofﬁce visits for pharyngitis. We
referred to this group as the IDSA-reduced popula-
tion (IDSA-RP) (Table 2). The percentage of patients
receiving a RADT was also varied to reﬂect adherence
to guideline recommendations [3]. Two scenarios of no
testing, no antibiotic treatment were also analyzed.
The no-testing, no-treatment option applied to the
NAMCS population was called NTX-NAMCS and its
application to the reduced population of pharyngitis
patients was the NTX-RP cohort (Table 2).
Calculation of Direct Costs
The estimated direct cost of each cohort characteristic
was calculated as the product of its unit cost (Table 1)
and frequency (Table 2). Total annual direct costs were
then calculated. The direct expenditure per patient
encounter was calculated for the NAMCS and IDSA-
NAMCS groups, by dividing their total annual direct
costs by their population size. It was not calculated for
the reduced population cohorts (IDSA-RP and NTX-
Table 1 Unit prices for direct costs
Category Unit price ($)
Professional services for pharyngitis 68.00
RADT 17.00
Recommended antibiotic course 7.00
Nonrecommended antibiotic course 30.00
Drug rash 60.00
Anaphylaxis 13,922.00
RADT, rapid antigen diagnostic test.
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RP), because they were created by proportional re-
ductions of the IDSA-NAMCS and NTX-NAMCS
cohorts. Therefore, patient expenditure per encounter
would be similar to those groups.
Calculation of Resistance Costs
Antibiotic consumption at the population level is a
recognized cause of DRSP [19–22]. Therefore, we esti-
mated single-year costs resulting from DRSP CAP
leading to hospitalization with full recovery. We did
not include resistance expenditures attributable to
development of newer and more expensive drugs,
because they are not generally assumed by the payer
[23].
Annual resistance costs were calculated using PDV€,
where P is the prevalence of DRSP in the community,
DV, whose components are shown in Table 3, repre-
sents the likelihood of hospitalization with DRSP CAP
multiplied by its cost, and € represents the propor-
tional effect of antibiotic use on resistance [24]; that is,
when antibiotic use for pharyngitis is intense, we
assumed that € = 1, moderate € = 0.5, and low € = 0.1.
Therefore, € reﬂects the elasticity of the effects of
antibiotic use on resistance rates. One would expect
respective resistance rates to increase or decrease
during periods of intense or reduced antibiotic use
[24]. In the primary analysis of resistance expenditures
in the NAMCS group, we arbitrarily set € at 1 to reﬂect
the high level of antibiotic use in this group. In
the antibiotic-sparing IDSA-NAMCS and IDSA-RP
cohorts, resistance rates should be lower, reﬂecting less
intense use of antibiotics. In these groups, € was arbi-
trarily set at 0.5 or 0.1, respectively.
To calculate the cost effects of resistance (PDV €),
we placed P at 0.20, reﬂecting a reasonable estimate of
DRSP in the United States [25,26]. To determine DV
for hospitalization with DRSP CAP, we calculated the
product of its likelihood multiplied by its cost as
shown in Table 3. The product of P and DV was then
multiplied by the different values of €, reﬂecting dif-
ferences in the intensities of antibiotic use. Therefore,
we studied the impacts of the different treatment strat-
egies on the price of antibiotic resistance. As noted
previously, in the primary analyses of resistance costs €
was assessed at three levels: € = 1, correlated with the
NAMCS cohort; € = 0.5, correlated with the IDSA-
NAMCS cohort; and € = 0.1, correlated with the
IDSA-RP cohort. In secondary analyses, we tested
assumptions made about €. For the NAMCS cohort,
we evaluated a range of € from 0.8 to 1; for the
IDSA-NAMCS cohort a range of € from 0.3 to 0.7 was
tested; and for the IDSA-RP cohort € was tested at
values of 0.1 and 0.2. Aggregate resistance expendi-
tures were calculated as the product of resistance costs
from a single antibiotic course and the annual number
of antibiotic prescriptions. The contribution of resis-
Table 2 Characteristics of cohorts
Variable NAMCS IDSA-NAMCS NTX-NAMCS IDSA-RP NTX-RP
Patients seeking medical care for pharyngitis 6.7 million 6.7 million 6.7 million 4.7 million 4.7 million
Patients receiving antibiotic therapy* 4.9 million (73%) 871,000 (13%) 0 611,000 (13%) 0
Patients receiving RADT* 5.36 million (80%) 2.7 million (41%) 0 1.9 million (41%) 0
Patients receiving recommended antibiotics† 1.1 million (22%) 871,000 (100%) 0 611,000 (100%) 0
Patients receiving nonrecommended antibiotics† 3.8 million (78%) 0 0 0 0
Antibiotic-related rash† 147,000 (3%) 26,130 (3%) 0 18,330 (3%) 0
Antibiotic-related anaphylaxis† 4,900 (0.1%) 871 (0.1%) 0 611 (0.1%) 0
*The number and percentage of pharyngitis patients in each cohort who received antibiotic therapy or a RADT.
†The number and percentage of antibiotic-receiving patients in each cohort who received a recommended or nonrecommended antibiotic, or experienced an antibiotic-related
rash or anaphylaxis.
IDSA, Infectious Diseases Society ofAmerica;NAMCS,NationalAmbulatory Medical Care Survey;NTX, no treatment; RADT, rapid antigen diagnostic test; RP, reduced population.
Table 3 Components used to calculate DV (cost consequence of DRSP)
Nonmonetary components of DV Frequency Reference
Annual adult episodes of CAP 4 million [46]
A. Patients hospitalized 0.15 (600,000) [46]
B. Hospitalizations with S. pneumoniae* 0.50 (300,000) [46,47]
C. Hospitalized patients with DRSP† 0.20 (60,000) [25,26]
Monetary components of DV Unit price ($) NA
D. Single hospitalization with DRSP‡ 29,000 NA
Calculation of DV (0.15)(0.50)(0.20)(29,000) [24]
DV ($) 435 NA
*Based on epidemiological data indicating that about 50% of episodes of CAP are caused by S. pneumoniae.
†Based on data indicating that at least 20% of S. pneumoniae isolates would be DRSP.
‡Additional Medicare reimbursement to authors’ institution for hospitalization with drug resistant CAP.
CAP, community-acquired pneumonia; DRSP, drug-resistant Streptococcus pneumonia; NA, not applicable.
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tance to the price of each patient encounter was cal-
culated as the difference of the total cost and direct
cost divided by the cohort size.
Results
Total Direct Costs
In the analysis of the NAMCS cohort, total direct
expenditure for 1 year was $745 million ($111 per
patient encounter), with antibiotic treatment-related
costs (RADT, prescriptions, adverse reactions)
accounting for 39% ($290 million) and professional
fees accounting for 61% ($455 million). Antibiotic
prescriptions for nonrecommended agents comprised
93% of total prescription costs (Table 4). Implemen-
tation of the IDSA guidelines to the NAMCS popula-
tion (IDSA-NAMCS) resulted in total direct costs
of $522 million ($78 per patient encounter), a 30%
reduction. In this scenario, costs related to antibiotic
treatment comprised 13% of the total with profes-
sional fees accounting for the remainder. Because only
recommended antibiotics were used, prescription costs
were reduced by 95% ($115 million) (Table 4). Evalu-
ation of the IDSA-RP group resulted in total direct
costs of $366 million, with antibiotic prescriptions
accounting for 1.1%. Applying the no-testing,
no-treatment option to the NAMCS population
(NTX-NAMCS) would result in an annual direct cost
of $455 million ($68 per patient encounter), reﬂecting
a 39% ($290 million) reduction over the NAMCS
group and a 13% ($67 million) reduction over the
IDSA-NAMCS group. Finally, the direct costs of a
no-treatment option applied to the population of 4.7
million adults with pharyngitis (NTX-RP) would be
$320 million, decreasing costs by 58% over the
NAMCS cohort, 39% over the IDSA-NAMCS cohort,
and 12% over the IDSA-RP cohort (Table 4).
Resistance Costs
In the primary analyses of resistance expenditures, we
assumed intense antibiotic use in the NAMCS cohort
and set € = 1. The estimated price of resistance, calcu-
lated as the resistance cost for a single antibiotic course
multiplied by the total number of prescriptions, was
$426 million. For the IDSA-NAMCS and IDSA-RP
primary analyses, we placed € at 0.5 and 0.1 to reﬂect
reduced antibiotic use for pharyngitis. Resistance costs
were $37.9 million and $5.3 million, respectively
(Table 5). Thus, the no-antibiotic-treatment option
would save an additional $5.3 million compared to
IDSA-RP.
Because the value of € in the primary analyses was
arbitrary, based on the assumed level of antibiotic use
in each cohort, we conducted secondary analyses of
each group by using various levels of €. In the NAMCS
cohort, resistance costs could range from $326 million
(€ = 0.8) to $426 million (€ = 1). In the IDSA-NAMCS
cohort resistance costs spanned from $22.7 million
(€ = 0.3) to $53 million (€ = 0.7). Resistance costs for
the IDSA-RP cohort ranged from $5.3 million (€ = 0.1)
to $10.6 million (€ = 0.2).
Total Costs
Annual total costs, calculated by adding direct and
resistance costs, are shown in Figure 1. Resistance
costs in these calculations were derived from the
primary analyses of resistance expenditures, as
described previously. In the NAMCS cohort, total
costs were $1.2 billion ($179 per patient encounter),
while in the IDSA-NAMCS group they were $560
million ($84 per patient encounter), a 48% reduction.
Table 4 Total direct costs ($) associated with each cohort analysis*
Variable NAMCS IDSA-NAMCS NTX-NAMCS IDSA-RP NTX-RP
Ofﬁce visits 455 million 455 million 455 million 320 million 320 million
RADT 91 million 46 million 0 32 million 0
Recommended antibiotics 8 million 7 million 0 4 million 0
Nonrecommended antibiotics 114 million 0 0 0 0
Antibiotic-related rash 9 million 2 million 0 1 million 0
Antibiotic-related anaphylaxis 68 million 12 million 0 9 million 0
Total direct costs 745 million 522 million 455 million 366 million 320 million
*Costs in millions.
IDSA, Infectious Diseases Society ofAmerica;NAMCS,NationalAmbulatory Medical Care Survey;NTX, no treatment; RADT, rapid antigen diagnostic test; RP, reduced population.
Table 5 Resistance costs associated with antibiotic use for
pharyngitis
€, proportional effect of antibiotic
use on microbial resistance*
1.0 0.5 0.1
Resistance costs per single course
of antibiotics ($)†
87 43.50 8.70
Number of patients receiving
antibiotic therapy‡
4,900,000 871,000 611,000
Aggregate resistance costs ($
millions)§
426 37.9 5.3
*Proportional effects of varied rates of antibiotic use on resistance.Three levels of €
were evaluated: € = 1.0 corresponds to intense antibiotic use (NAMCS cohort);
€ = 0.5 corresponds to moderate antibiotic use (IDSA-NAMCS cohort); and € = 0.1
corresponds to limited antibiotic use (IDSA-RP cohort).
†Resistance costs were calculated as the product of PDV and € as described in the
Methods section.
‡The number of patients receiving antibiotic therapy in each analysis.
§Aggregate resistance costs are the product of resistance costs for a single course of
antibiotic and the number of patients receiving antibiotic therapy for the respective
level of €.
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Thus, antibiotic resistance increased the cost of a
patient encounter in the NAMCS cohort by 61%
($68), over the direct cost. Resistance added an addi-
tional 8% ($6) to the total cost per patient encounter
in the IDSA-NAMCS group. Reducing physician visits
by 30% and applying the IDSA guidelines (IDSA-RP)
resulted in total costs of $372 million ($79 per patient
encounter), reﬂecting a cost reduction from decreased
resistance expenditures of 6% ($5) per patient encoun-
ter, compared to the IDSA-NAMCS cohort. Moreover,
it represented a 44% ($100) per patient cost reduction
due to decreased resistance expenditures compared to
the NAMCS cohort. As noted previously, the NTX-RP
option would result in $320 million in health-care
costs, all attributable to professional services, reﬂect-
ing a 16% decrease in total expenditures compared to
the IDSA-reduced population analysis.
Discussion
Expert guidelines recommend antibiotic treatment of
pharyngitis only for adults presenting with either clini-
cal [11] or clinical plus microbiological evidence of
GAS infection [12]. Contrary to this recommendation,
many physicians continue to prescribe antibiotics to
patients with a low probability of GAS [3]. Our COI
study showed that this practice could cost health
payers $1.2 billion annually in terms of direct expen-
ditures and those associated with the development of
antibiotic resistance. A unique ﬁnding of our work was
that antibiotic resistance may increase health-care
costs by 61% for each patient encounter. Several meth-
odological issues must be considered when interpreting
our conclusions.
The ﬁrst was the use of the NAMCS data to esti-
mate ofﬁce visits and prescribing patterns for adult
pharyngitis. This survey spanned the years of 1989 to
1999, and reported information only from nonfeder-
ally funded ofﬁce practices in the United States [5].
Although these data were collected during the previous
decade, they are the most recent longitudinal national
information about adult pharyngitis available. Because
the NAMCS reﬂects only information from nonfeder-
ally funded ofﬁce practices, it would underestimate
frequencies of ofﬁce visits and antibiotic prescriptions
for pharyngitis. In addition, we used Medicare reim-
bursement rates to assign costs, which may not provide
an accurate reﬂection of the price of health care. If
anything, we likely undervalued expenditures associ-
ated with pharyngitis management. Consistent with
this notion, the mean payment for ofﬁce visit costs was
$315 for claims ﬁled by an employed population with
pharyngitis or tonsillitis [13].
The second issue is the type of economic analysis
used. While a COI analysis highlights the economic
impact of a disease or its prevention, it does not
provide cost-effectiveness or cost-beneﬁt information
[16]. Quality-of-life measures are often omitted from
COI studies because of the difﬁculty accurately quan-
tifying them in monetary terms [16]. A related issue is
that we did not include all costs associated with phar-
yngitis. We decided a priori to omit some direct costs,
such as those associated with transportation, compli-
cations of GAS pharyngitis, and lost time from work.
Complications of GAS pharyngitis, such as acute
rheumatic fever (ARF) or peritonsillar abscess, were
omitted because they are rare in adult patients, and
there were no signiﬁcant differences in their rates with
or without antibiotic therapy [27–30]. Howie et al.
reported that the risk of ARF in children (around
1:40,000) was similar regardless of whether antibiotic
therapy was administered [31]. This risk would be
even lower in adults, because ARF is mainly a disease
of school-age children [30]. Finally, because antibiotic
treatment does not speed return to work [28,32,33],
lost time from work would be similar for all pharyn-
gitis patients. These omitted expenditures would have
little or no impact on the conclusions of our study.
The third issue is the validity of the mathematical
model to measure antibiotic resistance costs. Although
resistance to both GAS and S. pneumoniae have both
been linked to antibiotic consumption at the popula-
tion level [19–22,34,35], we estimated resistance costs
generated by DRSP because its consequences have
been deﬁned better than those of resistant GAS [7].
The cost of resistance model quantitatively incorpo-
rates economic principles of resistance by linking its
prevalence and cost consequences to different levels
of antibiotic use [24]. Its characteristics gave us the
ability to determine incremental cost changes at
various intensities of antibiotic use. We showed that
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Figure 1 Total costs (direct and resistance costs) associated with each
cohort analyzed. IDSA, Infectious Diseases Society of America; NAMCS,
National Ambulatory Medical Care Survey; NTX, no treatment; RP,
reduced population.
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resistance costs, as measured by hospitalization with
DRSP, varied proportionately with antibiotic con-
sumption, emphasizing the sensitivity of the relation-
ship between consumption and resistance [21,36]. Our
results probably underestimated the true cost of resis-
tance to the payer because we did not include other
expenditures such as death from resistant bacteria, nor
resistance developing in other bacteria. Nonetheless,
the preciseness of the results depends on how close the
relationship between antibiotic consumption and the
cost consequences of resistance approximates reality
[24]. Mathematical models rely on data based on
assumptions that have some degree of uncertainty, and
more studies using complex modeling to determine
resistance costs are clearly needed [36,37]. In the
meantime, the importance of our ﬁndings was that the
intensity of antibiotic use could be related proportion-
ately to resistance expenditures, a concept supported
by the work of others [24,36,37].
How can the results of our study be used by health-
care payers? This COI analysis highlights the areas of
antibiotic use and professional fees to target cost
reductions. Expenses in both areas could be curtailed
by development and implementation of educational
programs for clinicians that convey the epidemiology
and natural history of pharyngitis in otherwise healthy
adults, and the cost consequences of antibiotic resis-
tance. Excessive ofﬁce visits and antibiotic use for
pharyngitis stem from difﬁculties distinguishing GAS
infection from viral etiologies [2], physician and
patient overestimations of the consequences of
untreated GAS pharyngitis [27,29,38], and physicians’
expectations that patients want an antibiotic [39,40].
Contrary to physicians’ beliefs, most patients with URI
do not want an antibiotic [39]. Rather they seek
reassurance and education from their physician
[39]. Other investigators reported that patients who
received an antibiotic for pharyngitis were 25% more
likely to return to medical care for the same condition
[41,42]. Physicians must understand that providing
unnecessary antibiotic prescriptions promotes the
patient’s belief that an antibiotic is required for treat-
ment, leading to excessive ofﬁce visits, requests for
antibiotic prescriptions, and higher costs.
Physicians must also understand how their indi-
vidual prescribing habits contribute to health-care
expenditures [24,43]. Relatively small cost conse-
quences of resistance from a single antibiotic course
for pharyngitis can become quite large when applied to
all antibiotic courses for pharyngitis especially during
periods of intense antibiotic consumption. This unrec-
ognized outcome is rarely considered by physicians
[23,24,43]. A literature review found that multifaceted
educational programs were successful at reducing anti-
biotic prescribing [44]. Educational interventions con-
ducted in France reduced colonization rates with
resistant S. pneumoniae [21].
Finally, our study demonstrated that no antibiotic
treatment dominated other treatment strategies. Al-
though we did not measure health outcomes associ-
ated with no antibiotic treatment, routine antibiotic
treatment of GAS may not be required [27,29,30]. A
recent health outcomes study also found that foregoing
testing and treatment in children with pharyngitis had
both the lowest morbidity rate and costs from the
payer’s perspective [45]. Outcomes from no antibiotic
treatment of GAS pharyngitis await better delineation.
In the meantime, our study emphasized that better
adherence to IDSA guidelines was associated with sub-
stantial cost-savings to the health-care payer.
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